Rallybio

Rallybio P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Rallybio (RLYB) as of Oct 21, 2026 is -0.85. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -0.52 — a change of 65.30% (lower).

P/FCF

-0.85

YoY

65.30%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Rallybio is 2025 -0.85 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Rallybio was 2024 -0.52 . It decreases by 65.30% lower compared to the previous year.

The Rallybio P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2019
-1.67 USD
Jan 1, 2020
-1.15 USD
Jan 1, 2021
-0.55 USD
Jan 1, 2022
-0.44 USD
Jan 1, 2023
-0.42 USD
Jan 1, 2024
-0.52 USD
Jan 1, 2025
-0.85 USD
The Rallybio P/FCF history
YEARP/FCFYoY
-0.85+65.30%
-0.52+22.31%
-0.42-4.88%
-0.44-20.01%
-0.55-51.65%
-1.15-31.39%
-1.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rallybio Stock analysis

What does Rallybio do? Rallybio Corp. generates revenue by identifying, researching, and developing clinical biotechnology products and therapies for severe and rare diseases. The firm focuses on accelerating the development of life-transforming therapies, with a specific program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare hematological disease affecting fetuses and newborns. The company's pipeline includes several candidates such as RLYB212, a subcutaneously administered human monoclonal anti-HPA-1a antibody candidate for preventing HPA-1a maternal alloimmunization and FNAIT occurrence. Additionally, the advanced product candidate RLYB116 serves as an inhibitor of complement component 5 (C5) to treat complement dysregulation conditions including paroxysmal nocturnal hemoglobinuria (PNH) and generalized myasthenia gravis (gMG). The pipeline also features RLYB114, a pegylated C5-targeted Affibody molecule, and the ENPP1 Program, alongside RLYB331, targeting patients with these specific medical needs. Rallybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rallybio stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Rallybio is -0.85 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Rallybio changed from -0.52 to -0.85, representing a 65.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Rallybio since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Rallybio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Rallybio

All Key Metrics — Rallybio